Denali Therapeutics Inc
DNLI
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.09B
Close$
$0.96
94.5% downside
Current Fair Value
94.5% downsideOvervalued by 94.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.09 Billion |
|---|---|
| Enterprise Value | $2.91 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.97 |
| Beta | 1.02 |
| Outstanding Shares | 187,314,501 |
Return
| Return on Equity | -61.24% |
|---|---|
| Return on Assets | -44.17% |
| Return on Invested Capital | -49.99% |
Valuation & Multiples
| P/E Ratio | -6.85 |
|---|---|
| PEG | -247.54 |
| Price to Sales | - |
| Price to Book Ratio | 4.4 |
| Enterprise Value to Revenue | 808.24 |
| Enterprise Value to EBIT | -5.46 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
$2.15 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$12.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 94.17% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 84.06% |
|---|---|
| Total Invested | $411,051▼ 99.99% |
| Investors Holding | 5▼ 297.00% |
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts